PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Tiotropium"

Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis. “ Recurrent wheeze and breathlessness are common in people with cystic fib ...


Boehringer Ingelheim has informed the FDA ( Food and Drug Administration ) that ongoing safety monitoring has identified a possible increased risk of stroke in patients who take this Spiriva HandiHale ...


Aclidinium bromide ( Eklira, Bretaris ) has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease ( COPD ). The German Institute for Q ...


Researchers have evaluated the effect of dual, long acting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe chronic obstructive pulmonary disease ( COPD ).In t ...


Researchers have compared the efficacy and safety of Indacaterol ( Arcapta Neohaler, Onbrez Breezhaler ) and Tiotropium ( Spiriva ) in patients with severe chronic obstructive pulmonary disease ( COPD ...


Two once-daily long-acting muscarinic antagonists ( LAMAs ) are currently available for the treatment of chronic obstructive pulmonary disease ( COPD ), Tiotropium ( Spiriva ) and Glycopyrronium ( See ...


Glycopyrronium bromide ( NVA237; Seebri Breezhaler ) is a once-daily long-acting muscarinic antagonist ( LAMA ) in development for chronic obstructive pulmonary disease ( COPD ). The GLOW2 ( GLyco ...


Glycopyrronium ( Seebri Breezhaler ) is a once daily long-acting muscarinic antagonist that is approved for maintenance treatment of COPD ( chronic obstructive pulmonary disease ). This post-hoc poole ...


Inhaled Glycopyrronium bromide ( Seebri Breezhaler; NVA237 ) is a once-daily, long-acting muscarinic receptor antagonist ( LAMA ) that is approved in several countries, as a maintenance bronchodilator ...


COPD exacerbations are linked to a rapid decline in lung function and increased mortality. QVA149 ( Ultibro Breezhaler ) is a once-daily dual bronchodilator with a fixed-dose combination of long-actin ...


QVA149 ( Ultibro Breezhaler ), a novel, once-daily dual bronchodilator containing the long-acting beta2-agonist, Indacaterol and long-acting muscarinic antagonist Glycopyrronium, improves lung functio ...


Dual bronchodilation with a long-acting beta2-agonist ( LABA ) and long-acting muscarinic antagonist ( LAMA ) is recommended for patients with a high symptomatic burden and/or risk of exacerbations ( ...


Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease ( COPD ). A study has c ...


Despite currently available therapies and detailed guidelines, many people with mild asthma remain symptomatic; it is important to establish the efficacy and safety of new treatments in this group. ...


In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium ( Spiriva ) Respimat, a once-daily long-acting anticholinergic ...